Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome

Multiple Sclerosis

Volumn 20, Issue 1, 2014, Pages 35-42

  Orbach, Rotem ^a,b   Gurevich, Michael ^a   Achiron, Anat ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

biological markers; cerebrospinal fluid; clinically isolated syndrome; immunology; interleukin 12 subunit p40; Multiple sclerosis

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 12P40; EOTAXIN; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; VALIDATION STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; UPREGULATION;

BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; CLINICALLY ISOLATED SYNDROME; IMMUNOLOGY; INTERLEUKIN-12 SUBUNIT P40; MULTIPLE SCLEROSIS;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM DISEASES; DEMYELINATING DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ROC CURVE; YOUNG ADULT;

EID: 84890813415     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513491166     Document Type: Article

References (19)

1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
2. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: A consensus approach. Mult Scler. 2008 ; 14: 1157-1174
3. Solomon AJ, Klein EP, Bourdette D. "Undiagnosing" multiple sclerosis: The challenge of misdiagnosis in MS. Neurology. 2012 ; 78: 1986-1991
4. Spain R, Bourdette D. The radiologically isolated syndrome: Look (again) before you treat. Curr Neurol Neurosci Rep. 2011 ; 11: 498-506
5. Awad A, Hemmer B, Hartung HP, et al. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol. 2010 ; 219: 1-7
6. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
7. Johnson KS UpToDate. Basow DS, ed. MA: UpToDate in Waltham ; 2012 :
8. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. 2007 ; 256: S5 - S13
9. Iuliano G, Napoletano R, Esposito A. Multiple sclerosis: Relapses and timing of remissions. Eur Neurol. 2008 ; 59: 44-48
10. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin- 12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol. 1998 ; 16: 495-521
11. Brahmachari S, Pahan K. Role of cytokine p40 family in multiple sclerosis. Minerva Med. 2008 ; 99: 105-118
12. Gee K, Guzzo C, Che Mat NF, et al. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009 ; 8: 40-52
13. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest. 2002 ; 110: 493-497
14. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 1995 ; 182: 1985-1996
15. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol. 1999 ; 45: 695-703
16. Jana M, Pahan K. Induction of lymphotoxin-alpha by interleukin-12 p40 homodimer, the so-called biologically inactive molecule, but not IL-12 p70. Immunology. 2009 ; 127: 312-325
17. Jana M, Pahan K. IL-12 p40 homodimer, but not IL-12 p70, induces the expression of IL-16 in microglia and macrophages. Mol Immunol. 2009 ; 46: 773-783
18. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 ; 13: 715-725
19. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008 ; 7: 796-804